Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (171-180 of 539) with videos related to

Pageof 54
Sort By:
BMC Cancer|November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trialsJoseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Anti-Cancer Drugs|June 24, 2010
Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myelomaThomas M Moehler, Reinhard Feneberg, Anthony Dick Ho, et al.
Haematologica|December 22, 2010
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesJérôme Moreaux, Bernard Klein, Régis Bataille, et al.
British Journal of Haematology|August 26, 2004
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myelomaMarleen H C Bakkus, Yasmina Bouko, Diana Samson, et al.
Blood|April 9, 2010
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvementSascha Dietrich, Stefan O Schönland, Axel Benner, et al.
Heart Rhythm|February 5, 2008
Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac deathArnt V Kristen, Thomas J Dengler, Ute Hegenbart, et al.
BMC Cancer|February 24, 2017
High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient settingKatharina Lisenko, Sandra Sauer, Thomas Bruckner, et al.
Journal of Cellular Physiology|January 22, 2008
Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesisThomas M Moehler, Sandra Sauer, Maximilian Witzel, et al.
Haematologica|February 22, 2008
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosisTilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Immunological Reviews|April 21, 2006
Microarray-based understanding of normal and malignant plasma cellsJohn De Vos, Dirk Hose, Thierry Rème, et al.
Pageof 54

Showing results (171-180 of 539) with videos related to

Sort By:
Pageof 54
BMC Cancer|November 22, 2023
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trialsJoseph Kauer, Emma P Freundt, Anita Schmitt, et al.
Anti-Cancer Drugs|June 24, 2010
Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myelomaThomas M Moehler, Reinhard Feneberg, Anthony Dick Ho, et al.
Haematologica|December 22, 2010
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesJérôme Moreaux, Bernard Klein, Régis Bataille, et al.
British Journal of Haematology|August 26, 2004
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myelomaMarleen H C Bakkus, Yasmina Bouko, Diana Samson, et al.
Blood|April 9, 2010
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvementSascha Dietrich, Stefan O Schönland, Axel Benner, et al.
Heart Rhythm|February 5, 2008
Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac deathArnt V Kristen, Thomas J Dengler, Ute Hegenbart, et al.
BMC Cancer|February 24, 2017
High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient settingKatharina Lisenko, Sandra Sauer, Thomas Bruckner, et al.
Journal of Cellular Physiology|January 22, 2008
Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesisThomas M Moehler, Sandra Sauer, Maximilian Witzel, et al.
Haematologica|February 22, 2008
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosisTilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Immunological Reviews|April 21, 2006
Microarray-based understanding of normal and malignant plasma cellsJohn De Vos, Dirk Hose, Thierry Rème, et al.
Pageof 54